1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. All News
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
4.340 USD   -8.63%
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about EXAGEN INC.
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/11Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11TRANSCRIPT : Exagen Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M
MT
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
GL
05/11Exagen Inc. Reports First Quarter 2022 Results
GL
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
AQ
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
CI
05/11Exagen Inc. Reports First Quarter 2022 Results
AQ
05/11Exagen Inc. Revises Revenue Guidance for the Full Year of 2022
CI
05/01Exagen Announces Five-Week Campaign for Lupus Awareness Month
AQ
05/01Exagen Announces Five-Week Campaign for Lupus Awareness Month
GL
04/28EXAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
04/25Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
AQ
04/20Exagen Inc. to Participate in Investor Summit Group's Q2 Conference
GL
03/30Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
AQ
03/30Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
CI
03/25KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating
MT
03/23Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating
MT
03/22EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
03/22TRANSCRIPT : Exagen Inc., Q4 2021 Earnings Call, Mar 22, 2022
CI
03/22Exagen Q4 Loss Widens, Revenue Flat; Full-Year Sales Guidance Trails Street View
MT
03/22EXAGEN : Reports Fourth Quarter and Full Year 2021 Results - Form 8-K
PU
03/22Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $12.7M, vs. Street Est of $11.7M
MT
03/22Earnings Flash (XGN) EXAGEN Posts Q4 Loss $-0.42, vs. Street Est of $-0.46
MT
03/22Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
AQ
03/22Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
GL
03/22Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
03/22Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/22Exagen Inc. Provides Revenue Guidance for the Full Year 2022
CI
03/16Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
GL
03/16Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
GL
03/16Exagen Inc. Announces Board Appointments
CI
03/09Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTec..
GL
03/08Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
GL
02/02Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Dia..
AQ
01/10EXAGEN INC. : Regulation FD Disclosure (form 8-K)
AQ
01/10Exagen, Queen Mary University to Collaborate on Molecular Signatures for Rheumatoid Art..
MT
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
AQ
01/09Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor..
CI
2021Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
GL
2021Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen..
GL
2021KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating
MT
2021EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021TRANSCRIPT : Exagen Inc., Q3 2021 Earnings Call, Nov 10, 2021
CI
2021Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K
PU
2021Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M
MT
2021Earnings Flash (XGN) EXAGEN Posts Q3 Loss $-0.42, vs. Street Est of $-0.47
MT
2021EXAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Exagen Inc. Reports Third Quarter 2021 Results
AQ
2021Exagen Inc. Provides Revenue Guidance the Full Year 2021
CI
2021Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics a..
AQ
2021Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
GL
2021Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More..
AQ
2021Exagen Inc. Partners with Inland Empire Health Plan
CI
2021EXAGEN : Refinances $27.2 Million of Debt
MT
2021EXAGEN : Announces $27.2 Million Debt Refinancing - Form 8-K
PU
2021EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021EXAGEN INC : . Announces $27.2 Million Debt Refinancing
AQ
2021Exagen Inc. Announces $27.2 Million Debt Refinancing
CI
2021EXAGEN : Showcases Eight Scientific Presentations at ACR's Virtual Annual Meeting in Novem..
AQ
2021EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021EXAGEN INC.(NASDAQGM : XGN) added to S&P Global BMI Index
CI
2021EXAGEN INC : . to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conf..
AQ
2021EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021EXAGEN : Posts Wider Q2 Loss, Higher Revenue; Company Maintains Full-Year Revenue Outlook
MT
2021EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating
MT
2021EXAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
2021EXAGEN : Earnings Flash (XGN) EXAGEN Reports Q2 Loss $-0.38, vs. Street Est of $-0.44
MT
2021EXAGEN : Earnings Flash (XGN) EXAGEN Posts Q2 Revenue $12.8M, vs. Street Est of $11.4M
MT
2021TRANSCRIPT : Exagen Inc., Q2 2021 Earnings Call, Aug 09, 2021
CI
1  2  3  4  5Next
Upcoming event on EXAGEN INC.